TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Pivotal Phase III, Open-label, Randomized, Controlled Multi-center Study of the Efficacy of L19IL2/L19TNF Neoadjuvant Intratumoral Treatment Followed by Surgery Versus Surgery Alone in Clinical Stage III B/C Melanoma Patients
Brief Summary: Phase III, open-label, randomized, controlled multi-center study of the efficacy of L19IL2/L19TNF neoadjuvant intratumoral treatment in Stage III B/C melanoma patients.


Options:
A: Arm Label: Vemurafenib, pill, twice daily; Type: EXPERIMENTAL; Interventions: Drug: Vemurafenib, Drug: Cobimetinib | Intervention Type: DRUG; Name: Vemurafenib; Assigned to Arm(s): Vemurafenib, pill, twice daily | Intervention Type: DRUG; Name: Cobimetinib; Assigned to Arm(s): Vemurafenib, pill, twice daily
B: Arm Label: Sequential D + T, THEN Pembrolizumab; Type: EXPERIMENTAL; Interventions: Drug: Dabrafenib, Drug: Trametinib, Drug: Pembrolizumab | Arm Label: Concurrent D + T AND Pembrolizumab; Type: EXPERIMENTAL; Interventions: Drug: Dabrafenib, Drug: Trametinib, Drug: Pembrolizumab | Arm Label: Pembrolizumab ONLY; Type: EXPERIMENTAL; Interventions: Drug: Pembrolizumab | Intervention Type: DRUG; Name: Dabrafenib; Assigned to Arm(s): Concurrent D + T AND Pembrolizumab, Sequential D + T, THEN Pembrolizumab | Intervention Type: DRUG; Name: Trametinib; Assigned to Arm(s): Concurrent D + T AND Pembrolizumab, Sequential D + T, THEN Pembrolizumab | Intervention Type: DRUG; Name: Pembrolizumab; Assigned to Arm(s): Concurrent D + T AND Pembrolizumab, Pembrolizumab ONLY, Sequential D + T, THEN Pembrolizumab
C: Arm Label: Arm 1: neoadjuvant + surgery; Type: EXPERIMENTAL; Interventions: Drug: L19IL2 + L19TNF, Procedure: Surgery | Arm Label: Arm 2: surgery alone; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Surgery | Intervention Type: DRUG; Name: L19IL2 + L19TNF; Assigned to Arm(s): Arm 1: neoadjuvant + surgery | Intervention Type: PROCEDURE; Name: Surgery; Assigned to Arm(s): Arm 1: neoadjuvant + surgery, Arm 2: surgery alone
D: Arm Label: Ipilimumab and Placebo matching Nivolumab; Type: EXPERIMENTAL; Interventions: Drug: Ipilimumab, Other: Placebo matching Nivolumab | Arm Label: Nivolumab and Placebo matching Ipilimumab; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab, Other: Placebo matching Ipilimumab | Intervention Type: DRUG; Name: Ipilimumab; Assigned to Arm(s): Ipilimumab and Placebo matching Nivolumab | Intervention Type: DRUG; Name: Nivolumab; Assigned to Arm(s): Nivolumab and Placebo matching Ipilimumab | Intervention Type: OTHER; Name: Placebo matching Ipilimumab; Assigned to Arm(s): Nivolumab and Placebo matching Ipilimumab | Intervention Type: OTHER; Name: Placebo matching Nivolumab; Assigned to Arm(s): Ipilimumab and Placebo matching Nivolumab

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Pivotal Phase III, Open-label, Randomized, Controlled Multi-center Study of the Efficacy of L19IL2/L19TNF Neoadjuvant Intratumoral Treatment Followed by Surgery Versus Surgery Alone in Clinical Stage III B/C Melanoma Patients
Brief Summary: Phase III, open-label, randomized, controlled multi-center study of the efficacy of L19IL2/L19TNF neoadjuvant intratumoral treatment in Stage III B/C melanoma patients.


Options:
A: Arm Label: Arm 1: neoadjuvant + surgery; Type: EXPERIMENTAL; Interventions: Drug: L19IL2 + L19TNF, Procedure: Surgery | Arm Label: Arm 2: surgery alone; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Surgery | Intervention Type: DRUG; Name: L19IL2 + L19TNF; Assigned to Arm(s): Arm 1: neoadjuvant + surgery | Intervention Type: PROCEDURE; Name: Surgery; Assigned to Arm(s): Arm 1: neoadjuvant + surgery, Arm 2: surgery alone
B: Arm Label: Pembrolizumab 2 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Pembrolizumab 10 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Investigator-Choice Chemotherapy (ICC); Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Paclitaxel, Drug: Dacarbazine, Drug: Temozolomide | Arm Label: ICC→Pembrolizumab 2 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab, Drug: Carboplatin, Drug: Paclitaxel, Drug: Dacarbazine, Drug: Temozolomide | Arm Label: ICC→Pembrolizumab 10 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab, Drug: Carboplatin, Drug: Paclitaxel, Drug: Dacarbazine, Drug: Temozolomide | Intervention Type: BIOLOGICAL; Name: Pembrolizumab; Assigned to Arm(s): ICC→Pembrolizumab 10 mg/kg, ICC→Pembrolizumab 2 mg/kg, Pembrolizumab 10 mg/kg, Pembrolizumab 2 mg/kg | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): ICC→Pembrolizumab 10 mg/kg, ICC→Pembrolizumab 2 mg/kg, Investigator-Choice Chemotherapy (ICC) | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): ICC→Pembrolizumab 10 mg/kg, ICC→Pembrolizumab 2 mg/kg, Investigator-Choice Chemotherapy (ICC) | Intervention Type: DRUG; Name: Dacarbazine; Assigned to Arm(s): ICC→Pembrolizumab 10 mg/kg, ICC→Pembrolizumab 2 mg/kg, Investigator-Choice Chemotherapy (ICC) | Intervention Type: DRUG; Name: Temozolomide; Assigned to Arm(s): ICC→Pembrolizumab 10 mg/kg, ICC→Pembrolizumab 2 mg/kg, Investigator-Choice Chemotherapy (ICC)
C: Intervention Type: BIOLOGICAL; Name: GM2-KLH vaccine; Assigned to Arm(s): N/A | Intervention Type: BIOLOGICAL; Name: QS21; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: adjuvant therapy; Assigned to Arm(s): N/A
D: Arm Label: Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Ipilimumab | Arm Label: Pembrolizumab Q2W; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Pembrolizumab Q3W; Type: ACTIVE_COMPARATOR; Interventions: Biological: Pembrolizumab | Intervention Type: BIOLOGICAL; Name: Pembrolizumab; Assigned to Arm(s): Pembrolizumab Q2W, Pembrolizumab Q3W | Intervention Type: BIOLOGICAL; Name: Ipilimumab; Assigned to Arm(s): Ipilimumab

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Synbiotic on Postoperative Complications After Liver Transplantation - A Randomized Double-blind Clinical Trial
Brief Summary: The purpose of this study is to evaluate the use of synbiotic in patients after liver transplantation and assess the effect of these agents on postoperative infections, antibiotic use, length of hospital stay, mortality and nutritional status.


Options:
A: Arm Label: I; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: II; Type: EXPERIMENTAL; Interventions: Drug: Probiotic Supplement | Intervention Type: DRUG; Name: Probiotic Supplement; Assigned to Arm(s): II | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): I
B: Arm Label: Probiotic; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Probiotic | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Probiotic; Assigned to Arm(s): Probiotic
C: Arm Label: Synbiotic; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Synbiotic | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Control | Intervention Type: DIETARY_SUPPLEMENT; Name: Synbiotic; Assigned to Arm(s): Synbiotic | Intervention Type: DIETARY_SUPPLEMENT; Name: Control; Assigned to Arm(s): Control
D: Arm Label: CONTROL; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: CONTROL | Arm Label: SYNBIOTIC; Type: EXPERIMENTAL; Interventions: Dietary Supplement: SYNBIOTIC | Intervention Type: DIETARY_SUPPLEMENT; Name: CONTROL; Assigned to Arm(s): CONTROL | Intervention Type: DIETARY_SUPPLEMENT; Name: SYNBIOTIC; Assigned to Arm(s): SYNBIOTIC

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Weight Loss Pilot Study in Postmenopausal Breast Cancer Survivors
Brief Summary: The primary objective of this pilot study is to determine the effect of weight loss on a wide range of biomarkers associated with risk of breast cancer recurrence in overweight and obese breast cancer survivors. We hypothesized that weight loss would result in a statistically significant improvement in biomarkers associated with risk of breast cancer recurrence.


Options:
A: Arm Label: Lymphedema Care Only; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Exercise only; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise Intervention | Arm Label: Weight loss only; Type: EXPERIMENTAL; Interventions: Behavioral: Weight Loss Intervention | Arm Label: Exercise and Weight loss combined; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise Intervention, Behavioral: Weight Loss Intervention | Intervention Type: BEHAVIORAL; Name: Exercise Intervention; Assigned to Arm(s): Exercise and Weight loss combined, Exercise only | Intervention Type: BEHAVIORAL; Name: Weight Loss Intervention; Assigned to Arm(s): Exercise and Weight loss combined, Weight loss only
B: Arm Label: Self-regulation plus activity monitoring; Type: EXPERIMENTAL; Interventions: Behavioral: Self-regulation plus activity monitoring | Arm Label: Self-regulation; Type: EXPERIMENTAL; Interventions: Behavioral: Self-regulation | Arm Label: Delayed intervention control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Self-regulation plus activity monitoring; Assigned to Arm(s): Self-regulation plus activity monitoring | Intervention Type: BEHAVIORAL; Name: Self-regulation; Assigned to Arm(s): Self-regulation
C: Intervention Type: BEHAVIORAL; Name: Aerobic Exercise Training; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Resistance Exercise Training; Assigned to Arm(s): N/A
D: Arm Label: Calorie restricted diet plus exercise; Type: EXPERIMENTAL; Interventions: Other: Calorie restricted diet plus exercise | Arm Label: Weight management classes; Type: ACTIVE_COMPARATOR; Interventions: Other: Weight management classes | Intervention Type: OTHER; Name: Calorie restricted diet plus exercise; Assigned to Arm(s): Calorie restricted diet plus exercise | Intervention Type: OTHER; Name: Weight management classes; Assigned to Arm(s): Weight management classes

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Oxytocin-based Pharmacotherapy for Autism Spectrum Disorders: Investigating the Neural and Behavioral Effects of a Promising Intervention Approach
Brief Summary: The current trial aims to explore the neural and behavioral effects of oxytocin in autism spectrum disorders (ASD). Oxytocin is a nonapeptide produced by the paraventricular and supraoptic nuclei of the hypothalamus and is known to play a pivotal role in a variety of complex social behaviors. Initial studies showed that intranasal administration of oxytocin can have a positive effect on social functioning in ASD.

However, future studies are necessary to explore whether and how oxytocin effects neural processes in the brain underlying these behavioral improvements. This trial will not only measure behavioral enhancements, but will specifically focus on elucidating the associated neurophysiological changes by guiding the administration of oxytocin with regular neurophysiological assessments.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Memantine - Extended Release (ER) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Memantine - Extended Release (ER); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: Memantine; Type: EXPERIMENTAL; Interventions: Drug: Memantine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): Memantine | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Aripiprazole; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): Aripiprazole | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Syntocinon (Oxytocin, product code RVG 03716); Type: EXPERIMENTAL; Interventions: Drug: Syntocinon (Oxytocin) | Arm Label: Placebo (Physiological water(sodium chloride (NaCl) solution)); Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo (Physiological water (solution of sodium chloride (NaCl) in water)) | Intervention Type: DRUG; Name: Syntocinon (Oxytocin); Assigned to Arm(s): Syntocinon (Oxytocin, product code RVG 03716) | Intervention Type: OTHER; Name: Placebo (Physiological water (solution of sodium chloride (NaCl) in water)); Assigned to Arm(s): Placebo (Physiological water(sodium chloride (NaCl) solution))

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Oxytocin-based Pharmacotherapy for Autism Spectrum Disorders: Investigating the Neural and Behavioral Effects of a Promising Intervention Approach
Brief Summary: The current trial aims to explore the neural and behavioral effects of oxytocin in autism spectrum disorders (ASD). Oxytocin is a nonapeptide produced by the paraventricular and supraoptic nuclei of the hypothalamus and is known to play a pivotal role in a variety of complex social behaviors. Initial studies showed that intranasal administration of oxytocin can have a positive effect on social functioning in ASD.

However, future studies are necessary to explore whether and how oxytocin effects neural processes in the brain underlying these behavioral improvements. This trial will not only measure behavioral enhancements, but will specifically focus on elucidating the associated neurophysiological changes by guiding the administration of oxytocin with regular neurophysiological assessments.


Options:
A: Arm Label: Oxytocin; Type: EXPERIMENTAL; Interventions: Drug: Intranasal Oxytocin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Intranasal Oxytocin; Assigned to Arm(s): Oxytocin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: Risperidone, divalproex; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: atomoxetine, Behavioral: Parent Management Training | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: atomoxetine | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Behavioral: Parent Management Training | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: atomoxetine; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3, 4 | Intervention Type: BEHAVIORAL; Name: Parent Management Training; Assigned to Arm(s): 1, 3
D: Arm Label: Syntocinon (Oxytocin, product code RVG 03716); Type: EXPERIMENTAL; Interventions: Drug: Syntocinon (Oxytocin) | Arm Label: Placebo (Physiological water(sodium chloride (NaCl) solution)); Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo (Physiological water (solution of sodium chloride (NaCl) in water)) | Intervention Type: DRUG; Name: Syntocinon (Oxytocin); Assigned to Arm(s): Syntocinon (Oxytocin, product code RVG 03716) | Intervention Type: OTHER; Name: Placebo (Physiological water (solution of sodium chloride (NaCl) in water)); Assigned to Arm(s): Placebo (Physiological water(sodium chloride (NaCl) solution))

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Oxytocin-based Pharmacotherapy for Autism Spectrum Disorders: Investigating the Neural and Behavioral Effects of a Promising Intervention Approach
Brief Summary: The current trial aims to explore the neural and behavioral effects of oxytocin in autism spectrum disorders (ASD). Oxytocin is a nonapeptide produced by the paraventricular and supraoptic nuclei of the hypothalamus and is known to play a pivotal role in a variety of complex social behaviors. Initial studies showed that intranasal administration of oxytocin can have a positive effect on social functioning in ASD.

However, future studies are necessary to explore whether and how oxytocin effects neural processes in the brain underlying these behavioral improvements. This trial will not only measure behavioral enhancements, but will specifically focus on elucidating the associated neurophysiological changes by guiding the administration of oxytocin with regular neurophysiological assessments.


Options:
A: Arm Label: IGF-1; Type: EXPERIMENTAL; Interventions: Drug: IGF-1 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo/saline | Intervention Type: DRUG; Name: IGF-1; Assigned to Arm(s): IGF-1 | Intervention Type: DRUG; Name: Placebo/saline; Assigned to Arm(s): Placebo
B: Arm Label: Syntocinon (Oxytocin, product code RVG 03716); Type: EXPERIMENTAL; Interventions: Drug: Syntocinon (Oxytocin) | Arm Label: Placebo (Physiological water(sodium chloride (NaCl) solution)); Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo (Physiological water (solution of sodium chloride (NaCl) in water)) | Intervention Type: DRUG; Name: Syntocinon (Oxytocin); Assigned to Arm(s): Syntocinon (Oxytocin, product code RVG 03716) | Intervention Type: OTHER; Name: Placebo (Physiological water (solution of sodium chloride (NaCl) in water)); Assigned to Arm(s): Placebo (Physiological water(sodium chloride (NaCl) solution))
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: N-acetylcysteine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: N-acetylcysteine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: Extended-release guanfacine; Type: EXPERIMENTAL; Interventions: Drug: extended-release guanfacine | Arm Label: Inactive placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Inactive placebo | Intervention Type: DRUG; Name: extended-release guanfacine; Assigned to Arm(s): Extended-release guanfacine

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Preterm newborns are born with lower vitamin D stores. Although vitamin D supplementation is recommended there is no consensus regarding the adequate dose of supplementation for preterm infants.


Options:
A: Arm Label: Devit-3 Oral Drop 400 IU; Type: OTHER; Interventions: Drug: Devit-3 Oral Drop | Arm Label: Devit-3 Oral Drop 800 IU; Type: ACTIVE_COMPARATOR; Interventions: Drug: Devit-3 Oral Drop | Arm Label: Devit-3 Oral Drop 1000 IU; Type: ACTIVE_COMPARATOR; Interventions: Drug: Devit-3 Oral Drop | Intervention Type: DRUG; Name: Devit-3 Oral Drop; Assigned to Arm(s): Devit-3 Oral Drop 1000 IU, Devit-3 Oral Drop 400 IU, Devit-3 Oral Drop 800 IU
B: Arm Label: 400 IU vitamin D; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cholecalciferol | Arm Label: 4000 IU vitamin D; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cholecalciferol | Intervention Type: DRUG; Name: Cholecalciferol; Assigned to Arm(s): 400 IU vitamin D, 4000 IU vitamin D
C: Arm Label: Sustained; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cholecalciferol | Arm Label: Diet-Limited; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Cholecalciferol | Intervention Type: DIETARY_SUPPLEMENT; Name: Cholecalciferol; Assigned to Arm(s): Diet-Limited | Intervention Type: DRUG; Name: Cholecalciferol; Assigned to Arm(s): Sustained
D: Arm Label: RUTF with Vitamin D; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D, Dietary Supplement: Ready to Use Therapeutic Food (RUTF) | Arm Label: RUTF with Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Ready to Use Therapeutic Food (RUTF) | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D; Assigned to Arm(s): RUTF with Vitamin D | Intervention Type: DIETARY_SUPPLEMENT; Name: Ready to Use Therapeutic Food (RUTF); Assigned to Arm(s): RUTF with Placebo, RUTF with Vitamin D

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double-Blind, Placebo-Controlled, Exploratory Phase IIa Study To Assess The Safety And Efficacy Of Orally Administered Epeleuton In NAFLD Patients.
Brief Summary: The purpose of this randomised, double-blind, placebo-controlled, parallel group study is to assess the safety and efficacy of orally administered Epeleuton capsules versus placebo in the treatment of adult patients with Non Alcoholic Fatty Liver Disease (NAFLD)


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pioglitazone | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin E | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Matching placebo | Intervention Type: DRUG; Name: Pioglitazone; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin E; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Matching placebo; Assigned to Arm(s): 3
B: Arm Label: Polyunsaturated fatty acid (Opti-EPA); Type: ACTIVE_COMPARATOR; Interventions: Drug: Polyunsaturated fatty acid (Opti-EPA) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Polyunsaturated fatty acid (Opti-EPA); Assigned to Arm(s): Polyunsaturated fatty acid (Opti-EPA) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo capsules | Arm Label: 1000 mg Epeleuton; Type: EXPERIMENTAL; Interventions: Drug: Epeleuton | Arm Label: 2000 mg Epeleuton; Type: EXPERIMENTAL; Interventions: Drug: Epeleuton | Intervention Type: OTHER; Name: Placebo capsules; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Epeleuton; Assigned to Arm(s): 1000 mg Epeleuton, 2000 mg Epeleuton
D: Arm Label: Ginseng trial; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Red ginseng | Intervention Type: DIETARY_SUPPLEMENT; Name: Red ginseng; Assigned to Arm(s): Ginseng trial

Answer: C